It’s MEPC cake sale THIS FRIDAY, SO GET BAKING EVERYONE 🙂
Thank you!
Thank you to those who gave up their time to collect on Sunday (2nd June) at Tesco Abingdon; Angela and John Day, Geoff and Brenda Fewings, Andy and Julia Gower, Dave Webb and Terry Saunders. A great collection, totalling: £447.66
We have another collection this month on Saturday 29th June at Millets Farm, Frilford, if anyone can help please let me know.
Sue
Good news! NICE approves Ocrevus (ocrelizumab) for primary progressive MS
Source MS Trust: The MS Trust is delighted that Ocrevus (ocrelizumab) has been approved by NICE for NHS treatment of early, inflammatory primary progressive MS.
NICE has approved Ocrevus for people with primary progressive MS if they:
- have had symptoms of primary progressive MS for 15 years or less and
- are able to walk 20 metres or more, with or without walking aids (up to EDSS 6.5) and
- have evidence of MS activity on MRI scans
This reverses an earlier decision by NICE to reject Ocrevus for PPMS. The final publication of this decision was paused to allow time for further discussions to take place between NICE, NHS England and drug manufacturer Roche. Read on.
MS Nurse appointments available
MS Nurse appointments available for Thursday 26th September from 10-3pm, 45 minute slots. Appointments open now to book in the diary.
Multiple Sclerosis News Today Daily Digest
Worth reading, the Ocrelizumab (Ocrevus) story, plus second and third items. But a warning to all, not all the comments are positive.
Multiple Sclerosis News Today
The Web’s Daily Resource for Multiple Sclerosis News
In the 05/13/2019 edition:
- MS News that Caught My Eye Last Week: Lemtrada Satisfaction, Limiting Tysabri’s PML Risk, MS and Pregnancy, Infusions Vs. Pills
- Ocrevus Approved in UK as First NHS Treatment for PPMS
- #AANAM – Ocrevus Effective in RRMS Patients with Poor Responses to Other DMTs, Early Trial Data Suggest
- #AANAM – Aubagio at Higher Dose Shows Long-term Efficacy in Variety of Patients, Trial Data Show
- I Survived a Marathon Comedy Festival
- #AANAM – Interferon Beta Exposure Does Not Seem to Increase Risk of Pregnancy Complications, Study Suggests
| Excerpts:MS News that Caught My Eye Last Week: Lemtrada Satisfaction, Limiting Tysabri’s PML Risk, MS and Pregnancy, Infusions Vs. Pills#AANAM – RRMS Patients Switching to Lemtrada Report Greater Satisfaction with Treatment and Improvements in Quality of Life I’m a self-proclaimed secondary progressive, rather than a remitting, multiple sclerosis (MS) person. But a year after round two of Lemtrada (alemtuzumab), I can agree with this report. Several of my symptoms are better, most notably my […]The post MS News that Caught My Eye Last Week: Lemtrada Satisfaction, Limiting Tysabri’s PML Risk, MS and Pregnancy, Infusions Vs. Pills appeared first on Multiple Sclerosis News Today. Read on » Ocrevus Approved in UK as First NHS Treatment for PPMSAfter first rejecting it due to cost-effectiveness concerns, the National Institute for Health and Care Excellence (NICE) has now approved the use of Ocrevus (ocrelizumab) for people in the U.K. with early, inflammatory primary progressive multiple sclerosis (PPMS). This means that PPMS patients living in the U.K. will now have access to Ocrevus treatment through the […]The post Ocrevus Approved in UK as First NHS Treatment for PPMS appeared first on Multiple Sclerosis News Today. Read on » #AANAM – Ocrevus Effective in RRMS Patients with Poor Responses to Other DMTs, Early Trial Data SuggestEarly, one-year data from the Phase 3 CHORDS study show that Ocrevus effectively prevents relapses and disease progression in relapsing-remitting multiple sclerosis (RRMS) patients who have had poor responses to other disease-modifying therapies. These interim results were presented at the 2019 annual meeting of the American Academy of Neurology (AAN) in the presentation, “One-year interim analysis results of the […]The post #AANAM – Ocrevus Effective in RRMS Patients with Poor Responses to Other DMTs, Early Trial Data Suggest appeared first on Multiple Sclerosis News Today. Read on » #AANAM – Aubagio at Higher Dose Shows Long-term Efficacy in Variety of Patients, Trial Data ShowAubagio taken as 14 milligram (mg) tablet once daily significantly reduces the risk of relapse in people with relapsing multiple sclerosis (MS) over time irrespective of their prior treatment history, a pooled analysis of Phase 2 and Phase 3 trial results show. The findings were presented at the 2019 American Academy of Neurology (AAN) Annual Meeting, […]The post #AANAM – Aubagio at Higher Dose Shows Long-term Efficacy in Variety of Patients, Trial Data Show appeared first on Multiple Sclerosis News Today. Read on » I Survived a Marathon Comedy FestivalExactly one year ago on this day of writing, I was down and out. This year, I’m not exactly fighting fit, but the same set of circumstances has pushed me the distance. But it didn’t floor me. OK, OK, I’ll stop with the pugilistic metaphors — it’s not exactly knocking you out! Last year, I […]The post I Survived a Marathon Comedy Festival appeared first on Multiple Sclerosis News Today. Read on » #AANAM – Interferon Beta Exposure Does Not Seem to Increase Risk of Pregnancy Complications, Study SuggestsExposure to interferon beta does not seem to increase the risk of complications during pregnancy in women with multiple sclerosis (MS), new research suggests. The data were presented in an oral presentation, “Pregnancy and Infant Outcomes with Interferon Beta: Data from the European Interferon Beta Pregnancy Registry and MS Preg study conducted in Finland and […]The post #AANAM – Interferon Beta Exposure Does Not Seem to Increase Risk of Pregnancy Complications, Study Suggests appeared first on Multiple Sclerosis News Today. Read on » |
General Meeting 13th June 2019
Notice of General Meeting
Notice is hereby given that a General Meeting (Meeting) of The M.S. Therapy Centre (Oxford) Ltd (Company) will be held at 37e, Innovation Drive, Milton Park, Abingdon, OX14 4RT on June 13th2019 at noon.
You will be asked to consider and vote on the resolution below. The resolution will be proposed as a special resolution.
SPECIAL RESOLUTION
A copy of the Articles is attached to this notice.
By order of the Board
Andrew John Gower
Director
Registered Office
37e, Innovation Drive
Milton Park
Abingdon
OX14 4RT
Registered number: 2318549
May 13th2019
Notes to the Notice of General Meeting
If any member wishes to appoint a proxy, or wishes to receive an electronic copy of the articles before the meeting, please contact the chairman at andrewgower8@gmail.com.
New date for cake sale
Friday 21st June, put it in your dairies, all sort of cakes needed please.
We both now have hope – MS sisters
Sisters Zoe Bowman and Vikki Langford were both diagnosed with multiple sclerosis within weeks of each other.
But while Vikki has been able to get treatment for her form of the condition, Zoe has not.
That is because Zoe has the primary progressive form of the disease for which there has been no treatment available on the NHS. Until now.
CAKE SALE UPDATE
The cake sale date has changed, it’s now going to be a Friday in June, date to follow.
MEPC cake sale next Thursday, get baking everyone!
Please bring in your cakes Thursday morning between 9-11.30 and if you would like to purchase some please do.
Many thanks and I’m looking forward to seeing lots of calorific cakes 🙂
